


## UF010

<b>Cat. No.:</b>	HY-18976												
<b>CAS No.:</b>	537672-41-6												
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>15</sub> BrN <sub>2</sub> O												
<b>Molecular Weight:</b>	271.15												
<b>Target:</b>	JAK; HDAC; NF-κB; Toll-like Receptor (TLR); MyD88; Interleukin Related												
<b>Pathway:</b>	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; Cell Cycle/DNA Damage; NF-κB; Immunology/Inflammation												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : ≥ 100 mg/mL (368.80 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.6880 mL	18.4400 mL	36.8800 mL
	5 mM	0.7376 mL	3.6880 mL	7.3760 mL
	10 mM	0.3688 mL	1.8440 mL	3.6880 mL

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases<sup>[1][2][3]</sup>.

### IC<sub>50</sub> & Target

HDAC1	HDAC2	HDAC3	HDAC6
1.42 μM	0.32 μM (IC <sub>50</sub> )	256.7 nM (IC <sub>50</sub> )	18.93 μM (IC <sub>50</sub> )

	HDAC8 3.97 $\mu\text{M}$ (IC <sub>50</sub> )	IL-6
<b>In Vitro</b>	<p>UF010 (500 nM, 4 days) leads to a significant reduction in rod production with a concomitant increase in Müller cells<sup>[1]</sup>.            UF010 (10-100 <math>\mu\text{M}</math>, 72 h) has cytotoxicity to B16F10 cells, MCF-7 cells, A549 cells, 4T1 cells, HEK-293 cells and HCEC cells<sup>[2]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay <sup>[2]</sup></p>	
	Cell Line:	B16F10 cells, MCF-7 cells, A549 cells, 4T1 cells, HEK-293 cells and HCEC cells
	Concentration:	10 $\mu\text{M}$ , 100 $\mu\text{M}$
	Incubation Time:	72 h
	Result:	Showed IC <sub>50</sub> values of 2.41 $\mu\text{M}$ for B16F10 cells, 20.81 $\mu\text{M}$ for A549 cells, 17.93 $\mu\text{M}$ for MCF-7 cells, 8.40 $\mu\text{M}$ for 4T1 cells, 98.52 $\mu\text{M}$ for HEK-293 cells, 95.4 $\mu\text{M}$ for HCEC cells.
<b>In Vivo</b>	<p>UF010 (15 mg/kg, Intraperitoneal injection, single dose) contributes considerably to the inflammatory regulation of hippocampal neurons in postoperative cognitive dysfunction (POCD) mice<sup>[4]</sup>.            UF010 (15 mg/kg, Intraperitoneal injection, single dose) has antitumor therapeutic efficacy in the 4T1-Luc tumor-bearing mouse model<sup>[5]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	postoperative cognitive dysfunction (POCD) mice <sup>[4]</sup>
	Dosage:	15 mg/kg
	Administration:	Intraperitoneal injection (i.p.)
	Result:	<p>Weakened the infiltration of CD4+ T cells and NK cells in hippocampal tissues.            Reduced inflammatory parameters in serum and hippocampal tissues, such as interleukin 6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-<math>\alpha</math>) levels.            Activated the NF-<math>\kappa</math>B/p65, JAK/STAT and TLR/MyD88 pathways.</p>
	Animal Model:	4T1-Luc tumor-bearing mouse model <sup>[5]</sup>
	Dosage:	15 mg/kg
	Administration:	Intraperitoneal injection (i.p.)
	Result:	<p>Inhibited the tumor growth rate percentage to 55.56, 38.36, 39.52% at days 7, 14, and 21.            Induced high levels of ROS generation, causing apoptosis-mediated tumor cell death.</p>

## CUSTOMER VALIDATION

- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- J Healthc Eng. 2021 Dec 3;2021:3433615.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- 
- [1]. Mattar P, et al. A Casz1–NuRD complex regulates temporal identity transitions in neural progenitors [J]. Scientific reports, 2021, 11(1): 3858.
- [2]. Pulya S, et al. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer [J]. European Journal of Medicinal Chemistry, 2022, 238: 114470.
- [3]. Dai Y, et al. Classical HDACs in the regulation of neuroinflammation[J]. Neurochemistry International, 2021, 150: 105182.
- [4]. Yang C X, et al. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction [J]. European Review for Medical & Pharmacological Sciences, 2020, 24(19).
- [5]. Pulya S, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer [J]. Journal of Medicinal Chemistry, 2023, 66(17): 12033-12058.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA